Land continued, "Taking into account these new estimates, we are now revising our revenue guidance for 2009 to $90 million to $94 million from the previous range of $96 million to $101 million. Even at the low end of the range, this will represent a year-over-year growth rate of greater than 22 percent from our 2008 revenues of $73.7 million."
Andrews concluded, "Clarient's business model built on a balanced revenue stream across multiple cancer types and technologies is well-positioned in the new environment of health reform and cost containment. The opportunities for Clarient to use its established commercial engine to bring new advanced tests to market are numerous and growing daily, and the greater predictability we now have will allow us to assertively pursue some exciting new opportunities while maintaining a focus on profitability and cash flow."
Clarient will hold a conference call to discuss third quarter 2009 results. The call will include a period for questions and answers.
Date: Tuesday, November 3, 2009
Time: 5:00 p.m. Eastern
Call-in Number: 1-888-549-7704 (domestic) 1-480-629-9857 (international)
Conference ID Number: 4177526
Web Replay: For those unable to participate during the live broadcast, a replay of the webcast will be archived at www.clarientinc.com/investor shortly after the call and will be available for one year.
Clarient combines innovative diagnostic technologies w
|SOURCE Clarient, Inc.|
Copyright©2009 PR Newswire.
All rights reserved